Letolizumab

From Wikipedia, the free encyclopedia
Letolizumab
Monoclonal antibody
TypeSingle-chain variable fragment
SourceHumanized (from mouse)
Targettumor necrosis factor related activation protein
Clinical data
Other namesBMS-986004
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC1734H2688N466O538S10
Molar mass38991.90 g·mol−1

Letolizumab (INN;[1] development code BMS-986004) is a humanized monoclonal antibody designed for the treatment of inflammatory diseases.

This drug was developed by Bristol-Myers Squibb.[2]

References[]

  1. ^ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 116" (PDF). WHO Drug Information. 30 (4).
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Letolizumab, American Medical Association.
Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by .

  • v
  • t
Retrieved from ""